Uncategorized
ONL Therapeutics receives approximately $1 million grant from NEI
The National Eye Institute has awarded ONL Therapeutics a grant worth almost $1 million to continue developing its lead therapeutic candidate ONL1204, according to a company press release.ONL1204 is a small molecule FAS inhibitor designed to protect retinal cells, including photoreceptors, from cell death that occurs in multiple retinal diseases.